שווי הפעילות העסקית: Eterna Therapeutics (ERNA)

Eterna Therapeutics (ERNA) developments in blood cell therapy are independent of economic cycle phases and seasonality, although the company requires long-term investments. Biomaterial delivery relies on a costly cooling system to preserve their properties. This chart of current share prices on GURU.Markets shows the enterprise value at -1.45, while the business combines the sale of RNA-technology platforms through research and development alliances.

Eterna Therapeutics (ERNA) invests in cell engineering for cancer therapy, creating long-term value through intellectual property. Analyzing the enterprise value considering net debt at -1.45, an investor sees the sum of capitalization and debt minus cash, which determines the actual price for a full buyout of the company and allows for an assessment of the asset's financial stability.